Reply to "Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Patients With Resectable Gastroesophageal Junction and Gastric Cancer"

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Comment

Sam C Wang et al. Ann Surg. 2017 Dec.

. 2017 Dec;266(6):e77.

doi: 10.1097/SLA.0000000000001641.

¹ Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Comment on

Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma.
Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Wang SC, et al. Ann Surg. 2016 Feb;263(2):292-7. doi: 10.1097/SLA.0000000000001189. Ann Surg. 2016. PMID: 25915915 Free PMC article.
Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Patients With Resectable Gastroesophageal Junction and Gastric Cancer.
Urabe M, Yamashita H, Seto Y. Urabe M, et al. Ann Surg. 2017 Dec;266(6):e76-e77. doi: 10.1097/SLA.0000000000001596. Ann Surg. 2017. PMID: 29136992 No abstract available.